Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (AU:IMC)
ASX:IMC
IMC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.11
Previous CloseN/A
Volume128.40K
Average Volume (3M)229.42K
Market Cap
€20.92M
Enterprise ValueAU$7.61M
Total Cash (Recent Filing)€7.74M
Total Debt (Recent Filing)AU$135.62K
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding268,219,970
10 Day Avg. Volume546,470
30 Day Avg. Volume229,416
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Immuron Limited News
PremiumCompany Announcements
Immuron CEO to Present at Coffee Microcaps Conference
PremiumCompany Announcements
BNY Mellon Increases Stake in Immuron Limited
PremiumCompany Announcements
Immuron Limited Announces Cessation of Securities
PremiumCompany Announcements
Immuron Limited Announces Quotation of New Securities on ASXPremiumCompany Announcements
Immuron Limited Announces Proposed Issue of Securities
PremiumCompany Announcements
Immuron Limited Issues New Shares Under Corporations Act ComplianceOptions Prices
Currently, No data available
---
Ownership Overview
0.26% Insiders
―
Mutual Funds
― Other Institutional Investors
99.74% Public Companies and
Individual Investors
IMC FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.05 and its highest was AU$0.11 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is €20.92M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Aug 29, 2025 which is in 32 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Feb 26, 2025. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.011.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 268,219,970 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in AU:IMC
Immuron Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:IMC Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.69%
12-Months-Change
Fundamentals
Return on Equity
-52.70%
Trailing 12-Months
Asset Growth
-40.75%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited (IMC) is an Australian biopharmaceutical company that focuses on the development and commercialization of oral immunotherapeutic products for the treatment of gut-mediated diseases. The company's core technology platform leverages polyclonal antibodies that target specific pathogens within the gastrointestinal tract, aiming to provide novel solutions for conditions such as travelers' diarrhea and non-alcoholic steatohepatitis (NASH). Immuron's flagship product, Travelan, is designed to reduce the risk of travelers' diarrhea, a common ailment affecting international travelers.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―